Lee, Hae-Young; Han, Ki-Hoon; Chung, Woo-Baek; Her, Sung-Ho; Park, Tae-Ho; Rha, Seung-Woon; Choi, So-Yeon; Jung, Kyung-Tae; Park, Jong-Seon; Kim, Pum-Joon; Lee, Jong-Min; Jeong, Myung-Ho; Shin, Eun-Seok; Gwon, Hyeon-Cheol; Han, Kyoo-Rok; Chae, Jei-Keon; Kim, Woo-Shik; Choi, Dong-Ju; Hong, Bum-Kee; Choi, Si-Wan; Chung, Namsik
Clinical therapeutics
2020Sep ; 17 ( 18 ) :.
PMID : 32921501
ÀúÀÚ »ó¼¼Á¤º¸
Lee, Hae-Young - Seoul National University Hospital, Seoul, South Korea.
Han, Ki-Hoon - Asan Medical Center, Seoul, South Korea.
Chung, Woo-Baek - Seoul St. Mary's Hospital, Seoul, South Korea.
Her, Sung-Ho - Daejeon St. Mary's Hospital, Daejeon, South Korea.
Park, Tae-Ho - Dong-A University Hospital, Busan, South Korea.
Rha, Seung-Woon - Korea University Guro Hospital, Seoul, South Korea.
Choi, So-Yeon - Ajou University Hospital, Suwan, South Korea.
Jung, Kyung-Tae - Eulji University Hospital, Daejeon, South Korea.
Park, Jong-Seon - Yeungnam University Hospital, Daegu, South Korea.
Kim, Pum-Joon - St. Mary's Hospital Eunpyeong, Seoul, South Korea.
Lee, Jong-Min - St. Mary's Hospital Uijeongbu, Seoul, South Korea.
Jeong, Myung-Ho - Chonnam National University Hospital, Gwangju, South Korea.
Shin, Eun-Seok - Ulsan University Hospital, Ulsan, South Korea.
Gwon, Hyeon-Cheol - Samsung Medical Center, Seoul, South Korea.
Han, Kyoo-Rok - Kangdong Sacred Heart Hospital, Gangdong-gu, South Korea.
Chae, Jei-Keon - Chonbuk National University Hospital, Jeollabuk-do, South Korea.
Kim, Woo-Shik - Kyung Hee University Hospital, Gangdong, South Korea.
Choi, Dong-Ju - Seoul National University Bundang Hospital, Seoul, South Korea.
Hong, Bum-Kee - Gangnam Severance Hospital, Seoul, South Korea.
Choi, Si-Wan - Chungnam National University Hospital, Daejeon, South Korea.
Chung, Namsik - Yonsei University Severance Hospital, Seoul, South Korea. Electronic address:
ABSTRACT
PURPOSE: Although the role of high-intensity lipid-lowering therapy in cardiovascular protection has broadened, concerns still exist about new-onset diabetes mellitus (NODM), especially in vulnerable patients. This study aimed to compare the effect of high-dose (4?mg/d) and usual dose (2?mg/d) pitavastatin on glucose metabolism in patients with hyperlipidemia and impaired fasting glucose (IFG).
METHODS: In this 12-month study, glucose tolerance and lipid-lowering efficacy of high-dose pitavastatin (4?mg [study group]) was compared with that of usual dose pitavastatin (2?mg [control group]) in patients with hyperlipidemia and IFG. The primary end point was the change of glycosylated hemoglobin (HbA(1c)) after 24 weeks of treatment. The secondary end points were as follows: (1) NODM within 1 year after treatment, (2) change of lipid parameters, (3) changes of adiponectin, and (4) change of blood glucose and insulin levels. FINDINGS: Of the total 417 patients screened, 313 patients with hypercholesterolemia and IFG were randomly assigned into groups. The mean (SD) change in HbA(1c) was 0.06% (0.20%) in the study group and 0.03% (0.22%) in the control group (P?=?0.27). Within 1 year, 27 patients (12.3%) developed NODM, including 12 (10.6%) of 113 patients in the study group and 15 (14.2%) of 106 in the control group (P?=?0.43). The study group had a significantly higher reduction of total cholesterol and LDL-C levels and a higher increase in apolipoprotein A1/apolipoprotein B ratio (0.68 [0.40] vs 0.51 [0.35], P?
keyword
hyperlipidemia; impaired fasting glucose; new-onset diabetes mellitus; pitavastatin
¸µÅ©